175 related articles for article (PubMed ID: 15319665)
1. The role of nucleoside and nucleotide reverse transcriptase inhibitor backbones in antiretroviral therapy.
Young B
J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S13-20. PubMed ID: 15319665
[TBL] [Abstract][Full Text] [Related]
2. New nucleoside/nucleotide backbone options: a review of recent studies.
Ruane PJ; DeJesus E
J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S21-9. PubMed ID: 15319666
[TBL] [Abstract][Full Text] [Related]
3. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
4. Resistance issues with new nucleoside/nucleotide backbone options.
Wainberg MA; Turner D
J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S36-43. PubMed ID: 15319668
[TBL] [Abstract][Full Text] [Related]
5. The ideal nucleoside/nucleotide backbone.
Gallant JE
J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S44-51. PubMed ID: 15319669
[TBL] [Abstract][Full Text] [Related]
6. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
7. A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm.
Lange J
Antivir Ther; 2001; 6 Suppl 3():45-54. PubMed ID: 11678472
[TBL] [Abstract][Full Text] [Related]
8. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
Piliero PJ
J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S2-S12. PubMed ID: 15319664
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside and nucleotide reverse transcriptase inhibitors in children.
Giaquinto C; Rampon O; Penazzato M; Fregonese F; De Rossi A; D'Elia R
Clin Drug Investig; 2007; 27(8):509-31. PubMed ID: 17638393
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
13. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
14. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
[TBL] [Abstract][Full Text] [Related]
16. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
Bongiovanni M; Tordato F
Curr Med Chem; 2006; 13(23):2789-93. PubMed ID: 17073629
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
Wirden M; Lambert-Niclot S; Marcelin AG; Schneider L; Ait-Mohand H; Brunet C; Angleraud F; Amard S; Katlama C; Calvez V
AIDS; 2009 Jan; 23(1):95-9. PubMed ID: 19050391
[TBL] [Abstract][Full Text] [Related]
19. [Role of etravirine in combination antiretroviral therapy].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
[TBL] [Abstract][Full Text] [Related]
20. Apricitabine--a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs.
Cox S; Southby J
Expert Opin Investig Drugs; 2009 Feb; 18(2):199-209. PubMed ID: 19236266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
